Get the Stockscreener App
19.29
1.11%
-0.1551
Summit Therapeutics Inc stock is traded at $19.29, with a volume of 2.23M.
It is down -1.11% in the last 24 hours and down -32.90% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$19.45
Open:
$19.53
24h Volume:
2.23M
Relative Volume:
0.64
Market Cap:
$14.30B
Revenue:
$956.00K
Net Income/Loss:
$-221.32M
P/E Ratio:
-60.28
EPS:
-0.32
Net Cash Flow:
$-142.25M
1W Performance:
-19.34%
1M Performance:
-32.90%
6M Performance:
+8.16%
1Y Performance:
+0.47%
1-Day Range:
$18.71
$19.64
1-Week Range:
$18.71
$26.45
52-Week Range:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
19.25 | 14.44B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.44 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.81 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.34 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
761.11 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
347.75 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
First disclosure of Phase II data for pumitamig - The Pharma Letter
Akeso's Lung Cancer Drug Faces US Approval Hurdles - Finimize
Summit Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingJuly 2025 Highlights & Advanced Technical Analysis Signals - beatles.ru
SVP, US Marketing at Summit Therapeutics Inc. Job - Mediabistro
Summit's High-Profile Drug Flops And Shares Crash - Investor's Business Daily
Today's Moving Stocks: Planet Labs, EchoStar, Robinhood, Summit Therapeutics, BioNTech, CVS Health - TheStreet
Summit plays defense for the first time as questions loom over Phase 3 lung cancer readouts - Endpoints News
Top Midday Decliners - MarketScreener
Summit Therapeutics Enters Oversold Territory (SMMT) - Nasdaq
Transcript : Summit Therapeutics Inc.Special Call - MarketScreener
Summit Therapeutics: Dethroning Merck Was Never Going To Be Straightforward - Seeking Alpha
Summit Therapeutics Shares Plunge After Lung Cancer Drug Data Disappoints - MSN
Akeso Drops Most in 3 Months on Mixed Drug Data From US Partner - Bloomberg.com
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch - MSN
Robinhood & Applovin, SpaceX & EchoStar, Summit Therapeutics - Yahoo Finance
Summit Therapeutics stock rises as H.C. Wainwright reiterates Buy rating - Investing.com
Summit Therapeutics Shares Tumble As Lung Cancer Drug Disappoints Abroad - Finimize
Summit Therapeutics Reveals Promising Phase III Trial Results - TipRanks
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Benzinga
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Summit Therapeutics stock sinks after lung cancer drug data disappoints - Investing.com
S&P 500 Futures Climb in Premarket Trading; Summit Therapeutics, AST SpaceMobile Lag - Barron's
Summit shares tumble on mixed data for lung cancer drug - MarketScreener
Summit Therapeutics Shares Fall Pre-Bell Following New Data From Late-Stage Study of Cancer Drug Candidate - MarketScreener
Summit Therapeutics: Buy Rating Affirmed on Strong HARMONi Study Results and Strategic Positioning - TipRanks
Positive Buy Rating for Summit Therapeutics Driven by Promising HARMONi Trial Results and Anticipated Stock Upside - TipRanks
Mixed results for Summit’s ivonescimab - The Pharma Letter
Summit Therapeutics stock rating reiterated at Market Outperform by JMP - Investing.com
Summit Therapeutics (SMMT) Reports Promising Phase III Trial Dat - GuruFocus
Retail Traders Flock To Summit Therapeutics After New Cancer Drug Data Shows Survival Gains - Stocktwits
Longer-Term Follow-Up of Western Patients Analysis (DCO: Sept 2025) - Placera.se
Breakthrough: Novel Cancer Drug Extends Survival to 16.8 Months in Global Lung Cancer TrialKey Data Released - Stock Titan
Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster - statnews.com
16.8-Month Survival Breakthrough: Summit's Novel Cancer Drug Shows Promise in Global Lung Cancer Trial - Stock Titan
Developing predictive dashboards with Summit Therapeutics Inc. dataCPI Data & AI Based Buy/Sell Signal Reports - Newser
Market reaction to Summit Therapeutics Inc.’s recent news2025 Biggest Moves & Verified Entry Point Detection - Newser
How to read the order book for Summit Therapeutics Inc.Insider Buying & Real-Time Stock Price Movement Reports - Newser
Why Summit Therapeutics (SMMT) Is Up 9.6% After Phase III Ivonescimab Data Revealed at IASLC 2025 - simplywall.st
Is Summit Therapeutics Inc. vulnerable to short sellersWeekly Trade Summary & High Accuracy Investment Entry Signals - خودرو بانک
Does Summit Therapeutics Inc. offer margin of safety2025 Retail Activity & Long-Term Growth Portfolio Plans - 뉴스영
What are the analyst revisions for Summit Therapeutics Inc.Is EXFY stock a good investment in YEARJuly 2025 Levels & Daily Chart Pattern Signals - خودرو بانک
Analyzing drawdowns of Summit Therapeutics Inc. with statistical tools2025 Year in Review & Fast Gain Stock Trading Tips - Newser
Is Summit Therapeutics Inc. benefiting from innovation trendsWeekly Investment Recap & Safe Swing Trade Setup Alerts - خودرو بانک
What are Summit Therapeutics Inc.’s growth leversMarket Movers & Verified Swing Trading Watchlists - خودرو بانک
Ranking Summit Therapeutics Inc. among high performing stocks via toolsJuly 2025 PostEarnings & Verified Chart Pattern Signals - Newser
Can Summit Therapeutics Inc. recover in the next quarterWeekly Risk Report & Growth-Oriented Investment Plans - Newser
Aug Highlights: What is Summit Therapeutics Inc. s revenue forecastBear Alert & Advanced Technical Signal Analysis - خودرو بانک
Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3 - Stocktwits
Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3 - MSN
market reaction to summit therapeutics inc.’s recent newsMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
Is it too late to sell Summit Therapeutics Inc.July 2025 Recap & Fast Gain Swing Alerts - Newser
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Summit Therapeutics Inc Stock (SMMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):